US › Healthcare

Cardiol Therapeutics Inc Class A (CRDL)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.86-2.11%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-8.6M

EPS

$-0.04

EPS estimate

$-0.09

EPS came in at -0.04 against a street estimate of -0.09 — a beat of 55.6%.

Key statistics

Market cap

$233.1M

Forward P/E

0.0

P/B

13.39

Book value

$0.15

EPS (TTM)

$-0.25

52-week high

$2.34

52-week low

$0.88

50-day MA

$1.55

200-day MA

$1.23

Beta

0.61

Analyst view

Analysts rate Cardiol Therapeutics Inc Class A a buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $8.52.

Shareholding

Insiders

2.36%

Institutions

25.84%

Largest institutional holders

Fund	Stake
Mmcap International Inc. Spc	13.14%
Tejara Capital Ltd	4.38%
Ikarian Capital, LLC	2.33%
Citadel Advisors Llc	0.68%
BOOTHBAY FUND MANAGEMENT, LLC	0.68%
Two Sigma Investments LLC	0.64%
INTEGRITY ALLIANCE, LLC.	0.33%
The Goldman Sachs Group Inc	0.28%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cardiol Therapeutics Inc Class A — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.